Analyst concerns put Clorox in focus

Clorox (CLX) is back on investors’ radar after Jefferies and JPMorgan highlighted a potentially difficult second half, pointing to inflation, geopolitical tensions, private label competition, and ongoing cost pressures as key challenges.

The recent analyst downgrades come on top of weaker price momentum. The share price is at US$96.66 after a 14.6% 90 day share price return decline and a 27.2% 1 year total shareholder return decline, suggesting sentiment has been softening for some time.

If this kind of defensive consumer name is on your radar, it can be helpful to see what else is moving and compare it with 18 top founder-led companies

With Clorox trading at US$96.66 and screens showing both a value score of 5 and a 33.7% intrinsic discount, is this a defensive staple on sale, or is the market already bracing for weaker growth?

Most Popular Narrative: 19.3% Undervalued

Clorox's most followed narrative pegs fair value at about $119.76, comfortably above the last close at $96.66. This puts the focus squarely on its long term earnings power and cash generation.

The updated analyst price target for Clorox has shifted slightly lower to reflect a fair value move from about $122.41 to $119.76. Analysts are factoring in recent target cuts tied to softer guidance, slower expected volume recovery, and modestly lower revenue growth, profit margin, and future P/E assumptions, partially offset by at least one small upward revision.

The narrative hinges on how modest revenue growth, gradual margin improvement, and a future earnings multiple come together to justify that higher fair value number. It blends cautious earnings expectations with a valuation profile that still assumes the market is willing to pay up for a steady consumer staple over time.

Result: Fair Value of $119.76 (UNDERVALUED)

However, that upside case could be challenged if sluggish category growth lingers or if intense price competition and private label pressure squeeze margins harder than expected.

Next Steps

With sentiment clearly mixed, this is a moment to look at the numbers yourself and decide how the story stacks up. To weigh both the potential upsides and the areas of concern in one place, start with 5 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that better match your goals, risk comfort, and income needs across different types of businesses.

• Target potential upside in quality names that screens flag as attractively priced using the 53 high quality undervalued stocks.
• Strengthen your portfolio’s income stream by reviewing companies featured in the 13 dividend fortresses.
• Dial back risk without stepping out of the market by scanning the 73 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.